LENSAR, Inc. (LNSR) Misses Q4 EPS by $1.43, Beats on Revenue
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/26/2026
- S&P 500 ends lower; chips tumble and Moderna rallies
- SpaceX weighs Starlink mobile service to US consumers, FT reports
- U.S. chip stocks retreat after Apple price hikes stoke fears over AI trade
- Morgan Stanley flags Fed hike risk if unemployment drops below 4%
- UBS trims AI portfolio exposure to semis and hardware after recent rally
- Needham Starts NeoVolta (NEOV) at Buy
- TD Cowen: 'Sober View Suggests Structural Alcohol Risks Are Overblown'
- Two major earthquakes strike Venezuela, killing at least 32 and injuring hundreds
- Hertz cuts guidance, announces notes and stock offerings, shares sink
- Wall St ends mixed as tech megacap declines outweigh upbeat chip outlook
LENSAR Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update
February 27, 2025 7:00 AM EST31 ALLY Robotic Cataract Laser Systems placed in Q4 2024, representing an 86% increase in ALLY placements in full year 2024 over 2023; Companys total installed systems increased to approximately 385 as of December 31, 2024, representing a 26% increase over 2023
Fourth quarter 2024 revenue increased 38% over fourth quarter 2023; Full-year revenue increased 27% over 2023
Recurring revenue exceeds $40 million for the full year; increased 23% over 2023
ORLANDO, Fla., Feb. 27, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (LENSAR or the Company), a global medical technology company focused on advanced robotic laser solutions for... More
